TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31059146
Drug: Hydrocortisone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (higher dose) in secondary adrenal insufficiency
Study: 31059146
Drug: Stable hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stable hydrocortisone and fludrocortisone therapy in primary adrenal insufficiency
Study: 28596150
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) + Alpha-lipoic acid (ALA) combination
Study: 24651301
Drug: AryoSeven (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AryoSeven (30 μg/kg, intravenously per week for 4 weeks)
Study: 24651301
Drug: NovoSeven (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoSeven (30 μg/kg, intravenously per week for 4 weeks)
Study: 22364530
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride toothpaste and gel (Elmex(®))
Study: 22364530
Drug: 0.12% spray-chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% spray-chlorhexidine (Perio-Aid(®))
Study: 19667268
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel (AC followed by paclitaxel)
Study: 19667268
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy without paclitaxel (AC only)
Study: 15025551
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks
Study: 10806696
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg orally
Study: 10806696
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (control)
Study: 1996187
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release diltiazem (maximum dose 360 mg daily)
Study: 1996187
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release diltiazem (minimum dose 120 mg)
Study: 1996187
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release diltiazem (up to 360 mg daily)
Study: 23307827
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (0.25 mg tablets)
Study: 19525834
Drug: Steroid caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid caudal epidural injections (CEI) containing 12 mL of xylocaine 2% and 1 mL of betamethasone dipropionate and betamethasone phosphate (2 + 5) mg/dL
Study: 19525834
Drug: Water for
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for Injection (WFI) caudal epidural injections containing 12 mL of xylocaine 2% and 8 mL of WFI
Study: 10382124
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, or clarithromycin, 500 mg tid)
Study: 10382124
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, and amoxicillin, 1,000 mg bid, or clarithromycin, 500 mg tid)
Study: 10382124
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, plus tetracycline, 500 mg qid, or doxycycline, 100 mg tid)
Study: 2789925
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICS 205-930
Study: 2789925
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ICS 205-930
Study: 795183
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate fatty ointment
Study: 1183219
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide ointment
Study: 30537098
Drug: Progesterone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (400 mg/day for 7 days)
Study: 22677752
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reamberin and cycloferon
Study: 22433807
Drug: Generally accepted
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generally accepted therapy
Study: 16855141
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone response to hypoglycemia in SSc and PsA patients
Study: 16855141
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone response to hypoglycemia in healthy controls
Study: 15087264
Drug: High procyanidin
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High procyanidin chocolate (200 mg of flavanols and related procyanidins)
Study: 15087264
Drug: Low procyanidin
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low procyanidin chocolate (less than 10 mg of polyphenols)
Study: 10958263
Drug: New serotonergic-noradrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New serotonergic-noradrenergic antidepressant
Study: 7956958
Drug: Planned chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Planned chronic injection sclerotherapy (at three weekly intervals)
Study: 7956958
Drug: Demand injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand injection sclerotherapy (after variceal bleeds only)
Study: 28956620
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CBT + sertraline)
Study: 28582570
Drug: Filorexant 10
Normalized name: Filorexant
DrugBank: Filorexant (DB12158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filorexant 10 mg
Study: 21533995
Drug: Levodopa/carbidopa 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 100 mg three times on day 1
Study: 21533995
Drug: Levodopa/carbidopa 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 100 mg with COMT-inhibitor entacapone (EN) on day 2
Study: 14627174
Drug: Budesonide/formoterol (Symbicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mg, two inhalations b.i.d.
Study: 2859077
Drug: Dexamphetamine sulphate
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine sulphate tablets 10 mg
Study: 2859077
Drug: Dexamphetamine sulphate
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine sulphate tablets 30 mg
Study: 2859077
Drug: Dexedrine Spansules
Normalized name: Dextroamphetamine Sulfate 5 MG Oral Capsule, Extended Release [DEXEDRINE SPANSULES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexedrine Spansules 10 mg
Study: 2859077
Drug: Mazindol 4
Normalized name: Mazindol
DrugBank: Mazindol (DB00579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mazindol 4 mg
Study: 2859077
Drug: Fencamfamin hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fencamfamin (DB01463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fencamfamin hydrochloride 60 mg
Study: 27550361
Drug: AZD5847 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5847 at 500 mg twice daily
Study: 27550361
Drug: AZD5847 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5847 at 500 mg once daily
Study: 27550361
Drug: AZD5847 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5847 at 1,200 mg once daily
Study: 27550361
Drug: AZD5847 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5847 at 800 mg twice daily
Study: 27550361
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoniazid, rifampin, ethambutol, and pyrazinamide (standard chemotherapy)
Study: 24907877
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 0.5% bupivacaine (Group B)
Study: 24907877
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 0.5% levobupivacaine (Group L)
Study: 24907877
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both groups (Group B and Group L)
Study: 21962098
Drug: Nasal carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal carbon dioxide (10 mL/s for 10 seconds per nostril)
Study: 18405155
Drug: Cetirizine Hydrochloride,
Normalized name: Cetirizine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine Hydrochloride, 10 mg orally, once daily for 10 days.
Study: 12514658
Drug: Zofenopril (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril (30-60 mg/day)
Study: 12514658
Drug: Lisinopril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5-10 mg/day)
Study: 10462245
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza vaccine (FLUAD)
Study: 8698756
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (150 mg/day) for seven days before operation
Study: 2016621
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) alone (CYC/ADR)
Study: 2016621
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent radiation therapy (CT/RT)
Study: 19042940
Drug: Trimethoprim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (100 mg)
Study: 6992677
Drug: Nitrofurantoin macrocrystals
Normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin macrocrystals (100 mg)
Study: 6992677
Drug: Trimethoprim-sulfamethoxazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (40 mg/200 mg)
Study: 31868819
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug and wedge-shaped pillow (WSP) treatment for 3 months after 2 weeks of drug only and drug plus WSP sequences.
Study: 31868819
Drug: Drug only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug only sequence for 2 weeks.
Study: 31868819
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug and WSP treatment after 3 months.
Study: 28671507
Drug: Clarithromycin (CLM)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CLM) 500 mg every 12 hours for 3 days with one-stage full-mouth ultrasonic debridement (FMUD)
Study: 17628232
Drug: Anti-integrin α4
Normalized name: Anti-alpha4 integrin
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-integrin α4 therapies
Study: 17628232
Drug: Immunostimulating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunostimulating therapy (granulocyte-monocyte colony-stimulating factor)
Study: 19627686
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies
Study: 15149889
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/day (Control)
Study: 9204086
Drug: Adapalene aqueous
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene aqueous 0.03% and 0.1% gels
Study: 9204086
Drug: Adapalene alcoholic
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene alcoholic 0.03% and 0.1% gels
Study: 9204086
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel vehicles or patch alone
Study: 3630816
Drug: MLCu250 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLCu250 + 0.3 mg estradiol releasing about 1 microgram per day
Study: 3630816
Drug: MLCu250 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLCu250 + 1.0 mg estradiol releasing about 3 micrograms per day
Study: 29147969
Drug: Dietary phospholipids
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary phospholipids (PLs) at 8.5 g kg‐1
Study: 29147969
Drug: Dietary phospholipids
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary phospholipids (PLs) at increasing levels (8.5 to 41.5 g kg‐1)
Study: 27648684
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg Engerix-B® with 0, 1, 6 month intervals
Study: 27648684
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg Kangtai hepatitis B vaccine with 0, 1, 6 month intervals
Study: 27648684
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg Kangtai hepatitis B vaccine with 0, 2 month intervals
Study: 27648684
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg Huabei hepatitis B vaccine with 0, 1, 6 month intervals
Study: 23153657
Drug: Switching therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching therapy for non-responders
Study: 22323416
Drug: Oral antidiabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetes drugs (OADs)
Study: 15739544
Drug: Enoxaparin treatment
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin treatment (40 mg subcutaneously once daily)
Study: 6438014
Drug: Enteral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutritional support (constant infusion of a defined diet by needle catheter jejunostomy, started at 12 hours postoperatively, reaching 3000 kcal/day within 72 hours)
Study: 6438014
Drug: Conventional nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nutritional treatment (control group)
Study: 31106550
Drug: Fentanyl (0.003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.003 mg/kg)
Study: 28296480
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG) - 3 classes per week for 12 weeks
Study: 28296480
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG) - 2 classes per week for 12 weeks
Study: 28296480
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG)
Study: 28296480
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG)
Study: 25272965
Drug: computer-assisted cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: computer-assisted cognitive-behavioral therapy and/or medication management (ITV)
Study: 24136890
Drug: Prognostic model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic model for overall survival (OS) in men treated with second-line chemotherapy
Study: 16617400
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA 15‐3, ICTP, and CEA
Study: 10700536
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (Group I, n=15)
Study: 10700536
Drug: Hypocaloric parenteral
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric parenteral nutrition (Group II, n=7)
Study: 10700536
Drug: Hypocaloric parenteral
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric parenteral nutrition (Group II)
Study: 1391107
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid therapy (Control Group I)
Study: 1391107
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy based on glycerol and aminoacid (Group III)
Study: 6437257
Drug: Leaflets (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflets (L)
Study: 6437257
Drug: Leaflets plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflets plus maintenance manual (L + M)
Study: 31567637
Drug: Split-dose polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose polyethylene glycol with electrolyte solution
Study: 31567637
Drug: Full single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full single-dose polyethylene glycol with electrolyte solution
Study: 22866767
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (≥3 concomitantly used antihypertensive medications)
Study: 22866767
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (≤2 concomitantly used antihypertensive medications)
Study: 20560814
Drug: g‐FOBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: g‐FOBT
Study: 17388709
Drug: Rapid initiation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid initiation of quetiapine (200 mg on day 1, 400 mg on day 2, 600 mg on day 3, 800 mg on day 4)
Study: 17388709
Drug: Conventional initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional initiation of quetiapine (50 mg on day 1, 100 mg on day 2, increased in 100 mg/day increments to reach 400 mg on day 5)
Study: 12392586
Drug: Endothelin-1 (ET-1)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET-1) infusion at 2.5 pmol min-1
Study: 12392586
Drug: Endothelin-1 (ET-1)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET-1) infusion at 10 pmol min-1
Study: 7750527
Drug: Low-dose BCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BCG (75 mg)
Study: 7750527
Drug: Standard-dose BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose BCG (150 mg)
Study: 2125243
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pravastatin daily for 24 weeks
Study: 2125243
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of pravastatin daily for 24 weeks
Study: 2125243
Drug: 24 gm
Normalized name: Lactated Ringer's Solution/Magnesium Sulfate 24 GM/500 ML Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 gm of cholestyramine daily for 24 weeks
Study: 2125243
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pravastatin plus 24 gm of cholestyramine daily for 24 weeks
Study: 374162
Drug: Phyllocontin Continus
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllocontin Continus tablets
Study: 437308
Drug: Alupent tablets
Normalized name: metaproterenol sulfate Oral Tablet [Alupent]
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alupent tablets
Study: 437308
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllocontin tablets alone
Study: 437308
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin tablets alone
Study: 437308
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllocontin tablets with inhaled Ventolin
Study: 437308
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin tablets with inhaled Ventolin
Study: 30393978
Drug: Fructose breath
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose breath tests (open twice and blinded once)
Study: 26233594
Drug: 3 IA
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 IA doses of PRP
Study: 26233594
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of PRP
Study: 26233594
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of HA
Study: 26233594
Drug: 3 IA
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 IA doses of PRP (early OA subgroup)
Study: 26233594
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment group (advanced OA subgroup)
Study: 25920297
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone (8 mg) and metoclopramide (10 mg)
Study: 25920297
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg) with normal saline solution (1.6 ml)
Study: 24013497
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH therapy (0.025 mg/kg/day)
Study: 24013497
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH therapy (0.05 mg/kg/day)